Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Can alloHSCT be avoided in Ph+ ALL?

Usman Ali Akbar • 19 Apr 2022
The 2022 Tandem Meetings
Acute Lymphoblastic Leukemia Leukemia

Usman Ali Akbar, MBBS, University of Louisville, Louisville, KY, debates whether allogeneic hematopoietic stem cell transplantation (alloHSCT) can be avoided in Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr Akbar argues that currently, alloHSCT still has an important role in Ph+ ALL as the relapse rate remains very high in this patient population, and more data and newer more effective drugs are required to stop performing alloHSCT. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Usman Ali Akbar

1:17
Safety and efficacy of new TKIs in Ph+ ALL
Usman Ali Akbar • 19 Apr 2022
0:58
Monoclonal antibodies for the treatment of adult ALL
Usman Ali Akbar • 19 Apr 2022

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals